Smoking is an Independent Marker of Poor Prognosis in Cutaneous Melanoma
DOI:
https://doi.org/10.2340/actadv.v103.3209Keywords:
cigarette, melanoma, metastasis, skin cancer, smoking, survivalAbstract
Previous studies have suggested that persistent tobacco smoking impairs survival in cutaneous melanoma, but the effects of smoking and other prognostic factors have not been described in detail. This study examined the association of smoking (persistent, former, or never) with melanoma-specific (MSS) and overall survival (OS) in patients with cutaneous melanoma treated in Southwest Finland during 2005 to 2019. Clinical characteristics were obtained from electronic health records for 1,980 patients. Smoking status was available for 1,359 patients. Patients were restaged according to the 8th edition of the tumour-node-metastasis (TNM) classification. Smoking remained an independent prognostic factor for inferior melanoma-specific survival regardless of age, sex, stage, and comorbidities. The hazard ratio of death from melanoma was 1.81 (1.27−2.58, p = 0.001) in persistent and 1.75 (1.28−2.40, p = 0.001) in former smokers compared with never smokers. In 351 stage IV patients, smoking was associated with increased melanoma-specific and overall mortality: median MSS 10.4 (6.5−14.3), 14.6 (9.1−20.1), and 14.9 (11.4−18.4) months, p = 0.01 and median OS 10.4 (6.5−14.3), 13.9 (8.6−19.2), and 14.9 (11.7−18.1) months, p = 0.01 in persistent, former, and never smokers, respectively. In conclusion, since smoking represents an independent modifiable poor prognostic factor in patients with cutaneous melanoma, smoking habits should be proactively asked about by healthcare professionals, in order to support smoking cessation.
Downloads
References
Eggermont AM, Spatz A, Robert C. Cutaneous melanoma. Lancet 2014; 383: 816-827.
https://doi.org/10.1016/S0140-6736(13)60802-8 DOI: https://doi.org/10.1016/S0140-6736(13)60802-8
Sondermeijer L, Lamboo LGE, de Waal AC, Galesloot TE, Kiemeney LALM, van Rossum M, et al. Cigarette Smoking and the risk of cutaneous melanoma: a case-control study. Dermatology 2020; 236: 228-236.
https://doi.org/10.1159/000502129 DOI: https://doi.org/10.1159/000502129
Pitkäniemi J, Malila N, Tanskanen T, Degerlund H, Heikkinen S, Seppä K. Cancer in Finland 2019. Cancer Society of Finland Publication No. 98, Helsinki 2021.
Jiang AJ, Rambhatla PV, Eide MJ. Socioeconomic and lifestyle factors and melanoma: a systematic review. Br J Dermatol 2015; 172: 885-915.
https://doi.org/10.1111/bjd.13500 DOI: https://doi.org/10.1111/bjd.13500
de Vries E, van de Poll-Franse LV, Louwman WJ, de Gruijl FR, Coebergh JW. Predictions of skin cancer incidence in the Netherlands up to 2015. Br J Dermatol 2005; 152: 481-488.
https://doi.org/10.1111/j.1365-2133.2005.06386.x DOI: https://doi.org/10.1111/j.1365-2133.2005.06386.x
Dusingize JC, Olsen CM, Pandeya N, Thompson BS, Webb PM, Green AC, et al. Smoking and cutaneous melanoma: findings from the QSkin Sun and Health Cohort Study. Cancer Epidemiol Biomarkers Prev 2018; 27: 874-881.
https://doi.org/10.1158/1055-9965.EPI-17-1056 DOI: https://doi.org/10.1158/1055-9965.EPI-17-1056
Gibson J a. G, Dobbs TD, Griffiths R, Song J, Akbari A, Whitaker S, et al. The association of smoking and socioeconomic status on cutaneous melanoma: a population-based, data-linkage, case-control study. Br J Dermatol 2020; 182: 1136-1147.
https://doi.org/10.1111/bjd.18526 DOI: https://doi.org/10.1111/bjd.18526
Freedman DM, Sigurdson A, Doody MM, Rao RS, Linet MS. Risk of melanoma in relation to smoking, alcohol intake, and other factors in a large occupational cohort. Cancer Causes Control 2003; 14: 847-857.
https://doi.org/10.1023/B:CACO.0000003839.56954.73 DOI: https://doi.org/10.1023/B:CACO.0000003839.56954.73
Odenbro A, Gillgren P, Bellocco R, Boffetta P, Håkansson N, Adami J. The risk for cutaneous malignant melanoma, melanoma in situ and intraocular malignant melanoma in relation to tobacco use and body mass index. Br J Dermatol 2007; 156: 99-105.
https://doi.org/10.1111/j.1365-2133.2006.07537.x DOI: https://doi.org/10.1111/j.1365-2133.2006.07537.x
Kessides MC, Wheless L, Hoffman-Bolton J, Clipp S, Alani RM, Alberg AJ. Cigarette smoking and malignant melanoma: a case-control study. J Am Acad Dermatol 2011; 64: 84-90.
https://doi.org/10.1016/j.jaad.2010.01.041 DOI: https://doi.org/10.1016/j.jaad.2010.01.041
Mills CM, Hill SA, Marks R. Altered inflammatory responses in smokers. BMJ 1993; 307: 911.
https://doi.org/10.1136/bmj.307.6909.911 DOI: https://doi.org/10.1136/bmj.307.6909.911
Song F, Qureshi AA, Gao X, Li T, Han J. Smoking and risk of skin cancer: a prospective analysis and a meta-analysis. Int J Epidemiol 2012; 41: 1694-1705.
https://doi.org/10.1093/ije/dys146 DOI: https://doi.org/10.1093/ije/dys146
Gershenwald JE, Scolyer RA. Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond. Ann Surg Oncol 2018; 25: 2105-2110.
https://doi.org/10.1245/s10434-018-6513-7 DOI: https://doi.org/10.1245/s10434-018-6513-7
Dimitriou F, Krattinger R, Ramelyte E, Barysch MJ, Micaletto S, Dummer R, et al. The World of melanoma: epidemiologic, genetic, and anatomic differences of melanoma across the Globe. Curr Oncol Rep 2018; 20: 87.
https://doi.org/10.1007/s11912-018-0732-8 DOI: https://doi.org/10.1007/s11912-018-0732-8
Lasithiotakis K, Leiter U, Meier F, Eigentler T, Metzler G, Moehrle M, et al. Age and gender are significant independent predictors of survival in primary cutaneous melanoma. Cancer 2008; 112: 1795-1804.
https://doi.org/10.1002/cncr.23359 DOI: https://doi.org/10.1002/cncr.23359
Chang CK, Hsieh YS, Chen PN, Chu SC, Huang JY, Wang YH, et al. A cohort study: comorbidity and stage affected the prognosis of melanoma patients in Taiwan. Front Oncol 2022; 12: 846760.
https://doi.org/10.3389/fonc.2022.846760 DOI: https://doi.org/10.3389/fonc.2022.846760
Warren GW, Kasza KA, Reid ME, Cummings KM, Marshall JR. Smoking at diagnosis and survival in cancer patients. Int J Cancer 2013; 132: 401-410.
https://doi.org/10.1002/ijc.27617 DOI: https://doi.org/10.1002/ijc.27617
Wang Y, Tao H, Paxton RJ, Wang J, Mubarik S, Jia Y, et al. Post-diagnosis smoking and risk of cardiovascular, cancer, and all-cause mortality in survivors of 10 adult cancers: a prospective cohort study. Am J Cancer Res 2019; 9: 2493-2514.
https://doi.org/10.1158/1538-7445.AM2019-2493 DOI: https://doi.org/10.1158/1538-7445.AM2019-2493
Karlsson A, Ellonen A, Irjala H, Väliaho V, Mattila K, Nissi L, et al. Impact of deep learning-determined smoking status on mortality of cancer patients: never too late to quit. ESMO Open 2021; 6: 100175.
https://doi.org/10.1016/j.esmoop.2021.100175 DOI: https://doi.org/10.1016/j.esmoop.2021.100175
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
https://doi.org/10.1097/00000421-198212000-00014 DOI: https://doi.org/10.1097/00000421-198212000-00014
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
https://doi.org/10.1016/0021-9681(87)90171-8 DOI: https://doi.org/10.1016/0021-9681(87)90171-8
Jones MS, Jones PC, Stern SL, Elashoff D, Hoon DSB, Thompson J, et al. The Impact of smoking on sentinel node metastasis of primary cutaneous melanoma. Ann Surg Oncol 2017; 24: 2089-2094.
https://doi.org/10.1245/s10434-017-5775-9 DOI: https://doi.org/10.1245/s10434-017-5775-9
Benowitz NL, Lessov-Schlaggar CN, Swan GE, Jacob P. Female sex and oral contraceptive use accelerate nicotine metabolism. Clin Pharmacol Ther 2006; 79: 480-488.
https://doi.org/10.1016/j.clpt.2006.01.008 DOI: https://doi.org/10.1016/j.clpt.2006.01.008
Moodie C, Best C, Critchlow N, Hitchman S, Stead M, McNeill A. The impacts of including information about the number of carcinogens in smoke on standardized cigarette packs in the UK. Eur J Public Health 2021; 31: 1031-1037.
https://doi.org/10.1093/eurpub/ckab101 DOI: https://doi.org/10.1093/eurpub/ckab101
Sobus SL, Warren GW. The biologic effects of cigarette smoke on cancer cells. Cancer 2014; 120: 3617-3626.
https://doi.org/10.1002/cncr.28904 DOI: https://doi.org/10.1002/cncr.28904
Petros WP, Younis IR, Ford JN, Weed SA. Effects of tobacco smoking & nicotine on cancer treatment. Pharmacotherapy 2012; 32: 920-931.
https://doi.org/10.1002/j.1875-9114.2012.01117 DOI: https://doi.org/10.1002/j.1875-9114.2012.01117
Zhang P, Nie X, Bie Z, Li L. Impact of heavy smoking on the benefits from first-line EGFR-TKI therapy in patients with advanced lung adenocarcinoma. Medicine (Baltimore) 2018; 97: e0006.
https://doi.org/10.1097/MD.0000000000010006 DOI: https://doi.org/10.1097/MD.0000000000010006
Qiu F, Liang CL, Liu H, Zeng YQ, Hou S, Huang S, et al. Impacts of cigarette smoking on immune responsiveness: Up and down or upside down? Oncotarget 2016; 8: 268-284.
https://doi.org/10.18632/oncotarget.13613 DOI: https://doi.org/10.18632/oncotarget.13613
Sillah A, Tykodi SS, Hall ET, Thompson JA, Watson NF, Lee SM, et al. Predictive lifestyle markers for efficacy of cancer immune checkpoint inhibitors: a commentary. Future Oncol 2021; 17: 363-369.
https://doi.org/10.2217/fon-2020-0730 DOI: https://doi.org/10.2217/fon-2020-0730
Peters EN, Torres E, Toll BA, Cummings KM, Gritz ER, Hyland A, et al. Tobacco assessment in actively accruing National Cancer Institute Cooperative Group Program Clinical Trials. J Clin Oncol 2012; 30: 2869-2875.
https://doi.org/10.1200/JCO.2011.40.8815 DOI: https://doi.org/10.1200/JCO.2011.40.8815
Mattila KE, Vihinen P, Ramadan S, Skyttä T, Tiainen L, Vuoristo MS, et al. Combination chemotherapy with temozolomide, lomustine, vincristine and interferon-alpha (TOL-IFN) plus vemurafenib or TOL-IFN as first-line treatment for patients with advanced melanoma. Acta Oncol 2020; 59: 310-314.
https://doi.org/10.1080/0284186X.2019.1670862 DOI: https://doi.org/10.1080/0284186X.2019.1670862
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Kalle Mattila, Helmi Vihinen, Antti Karlsson, Heikki Minn, Pia Vihinen, Eetu Heervä
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
